Revolution Medicines, Inc.

About Revolution Medicines, Inc.

Revolution Medicines is a company dedicated to discovering, developing, and delivering innovative, targeted medicines for patients with cancer, with a specific focus on RAS-addicted cancers. Their mission is to revolutionize treatment for these patients by pioneering cutting-edge therapeutic approaches.

Products & Services

RAS(ON) Inhibitors:A portfolio of inhibitors targeting RAS-addicted cancers using a tri-complex inhibitor platform, including daraxonrasib (RMC-6236), a multi-selective inhibitor; elironrasib (RMC-6291), a G12C-selective inhibitor; and zoldonrasib (RMC-9805), a G12D-selective inhibitor, along with a robust pre-clinical pipeline for additional RAS mutations.

Specialties

RAS-addicted cancer treatment Targeted cancer therapies Tri-complex inhibitor platform Oncology drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing and Debt T: - FT: Royalty Financing and Debt	A: 2000000000 MR: - FA: $2 billion FAN: 2000000000	D: 2025-06-24 FD: 2025-06-24	1 investors
2	RT: Synthetic Royalty Funding and Secured Debt T: - FT: Synthetic Royalty Funding and Secured Debt	A: 2000000000 MR: - FA: Up to $2 billion FAN: 2000000000	D: 2025-06-24 FD: 2025-06-24	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 862500000 MR: - FA: $862.5 million FAN: 862500000	D: 2024-12-05 FD: 2024-12-05	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 750000000 MR: - FA: 750.0 million FAN: 750000000	D: 2024-12-03 FD: 2024-12-03	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 600000000 MR: - FA: $600 million FAN: 600000000	D: 2024-12-02 FD: 2024-12-02	5 investors
6	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2023-03-01 FD: 2023-03-01	5 investors

Royalty Financing and Debt Latest

2025-06-24

$2.0B

1 investor (Pro only)

Synthetic Royalty Funding and Secured Debt 2025-06-24

$2.0B

Public Offering 2024-12-05

$862.5M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark A. Goldsmith

President, Chief Executive Officer and Board Chairman

S

Steve Kelsey

President, Research and Development

M

Margaret (Peg) Horn

Chief Operating Officer

W

Wei Lin

Chief Medical Officer

W

Wei Lin, M.D.

Chief Medical Officer

J

Jack Anders

Chief Financial Officer

View 22 more team members with Pro

Unlock Full Team Directory

Recent News